Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia - PubMed (original) (raw)

doi: 10.1016/s1535-6108(02)00018-1.

Donna S Neuberg, Jane Staunton, Mignon L Loh, Christine Huard, Susana C Raimondi, Fred G Behm, Ching Hon Pui, James R Downing, D Gary Gilliland, Eric S Lander, Todd R Golub, A Thomas Look

Affiliations

Free article

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

Adolfo A Ferrando et al. Cancer Cell. 2002 Feb.

Free article

Abstract

Human T cell leukemias can arise from oncogenes activated by specific chromosomal translocations involving the T cell receptor genes. Here we show that five different T cell oncogenes (HOX11, TAL1, LYL1, LMO1, and LMO2) are often aberrantly expressed in the absence of chromosomal abnormalities. Using oligonucleotide microarrays, we identified several gene expression signatures that were indicative of leukemic arrest at specific stages of normal thymocyte development: LYL1+ signature (pro-T), HOX11+ (early cortical thymocyte), and TAL1+ (late cortical thymocyte). Hierarchical clustering analysis of gene expression signatures grouped samples according to their shared oncogenic pathways and identified HOX11L2 activation as a novel event in T cell leukemogenesis. These findings have clinical importance, since HOX11 activation is significantly associated with a favorable prognosis, while expression of TAL1, LYL1, or, surprisingly, HOX11L2 confers a much worse response to treatment. Our results illustrate the power of gene expression profiles to elucidate transformation pathways relevant to human leukemia.

PubMed Disclaimer

Comment in

Similar articles

Cited by

Publication types

MeSH terms

Substances

LinkOut - more resources